What is Genomic Expression?
Genomic Expression operates at the intersection of biotechnology and artificial intelligence, specializing in advanced RNA analysis. Its flagship OneRNA platform serves as a critical tool for healthcare professionals, enabling precise disease detection, continuous health monitoring, and the accelerated design of next-generation cures. By facilitating the repurposing of approved drugs for individual patient profiles and streamlining the development of novel RNA therapeutics, the company addresses significant gaps in current cancer care protocols. The firm's commitment to scalability and AI-driven insights establishes it as a formidable player in the rapidly evolving landscape of molecular diagnostics and personalized medicine.
How much funding has Genomic Expression raised?
Genomic Expression has raised a total of $4.3M across 2 funding rounds:
Grant
$4.2M
Debt
$50K
Grant (2018): $4.2M, investors not publicly disclosed
Debt (2021): $50K led by PPP
Key Investors in Genomic Expression
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Genomic Expression?
With the recent influx of capital, Genomic Expression is poised to deepen its market penetration and enhance its therapeutic pipeline. The strategic focus will likely shift toward expanding the clinical utility of the OneRNA platform, fostering partnerships with major healthcare providers, and accelerating the regulatory pathways for its novel RNA-based treatments. As the company moves into this next phase of growth, the integration of advanced machine learning models will be paramount in maintaining its competitive edge, ensuring that the firm remains at the forefront of the RNA diagnostics and therapeutics industry.
See full Genomic Expression company page
